Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | GRK2 | P25098 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408604 | 0.91 | CA1 (0.66) | CA1CA2CA12CA9CA14 | |
| SCHEMBL7623 | 0.87 | CA1 (0.64) | CA1CA2CA12CA9CA14 | |
| Hydrochloric Acid SCHEMBL31520543 | 0.85 | CA1 (0.61) | CA1CA2CA12CA9CA14 | |
| SCHEMBL11254482 | 0.85 | CA1 (0.61) | CA1CA2CA12CA9CA14 | |
| Methane SCHEMBL2658014 | 0.85 | CA1 (0.61) | CA1CA2CA12CA9CA14 | |
| SCHEMBL30251598 | 0.84 | TSHR (0.64) | CA1CA2CA12CA9CA14 | |
| SCHEMBL866718 | 0.84 | TSHR (0.64) | CA1CA2CA12CA9CA14 | |
| SCHEMBL4248683 | 0.82 | CA1 (0.61) | CA1CA2CA12CA9CA14 | |
| SCHEMBL3297654 | 0.82 | CA1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL28823597 | 0.82 | CA1 (0.75) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609892-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2013-12-17 | — | — | US | disclosed |
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| US-7816557-B2 | 3-{4-[1-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}-propionic acid; treat diabetic and other glucagon related metabolic disorders | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2159221-A1 | Glucagon receptor antagonists, preparation and therapeutic uses | Eli Lilly & Company (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1758853-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | CA1 4194/4885CA2 2157/4885CA12 3776/4885 |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | CA1 4194/4885CA2 2157/4885CA12 3776/4885 |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | CA1 4194/4885CA2 2157/4885CA12 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.